Healios K.K. (OTCMKTS:HLOSF – Get Free Report) was the target of a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 263,933 shares, a decrease of 34.6% from the April 15th total of 403,733 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.
Healios K.K. Price Performance
OTCMKTS HLOSF remained flat at $2.20 during trading on Monday. Healios K.K. has a 1 year low of $1.90 and a 1 year high of $4.45. The company has a fifty day moving average price of $2.40 and a two-hundred day moving average price of $2.46.
Healios K.K. Company Profile
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Further Reading
- Five stocks we like better than Healios K.K.
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
- These Stocks Could Be the Biggest Winners of the 2026 Midterms
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
